EXPLORE THE EVIDENCE FOR MEDTRONIC RDN

Convincing and substantial evidence for the Medtronic Symplicity Spyral™ Renal Denervation (RDN) system

DOWNLOAD THE JACC MANUSCRIPT

CLINICALLY MEANINGFUL BP REDUCTION ACROSS 7,000 PATIENTS*1,2

The SPYRAL HTN Clinical Program features the most rigorous and extensive patient experience as shown in three randomized, sham-controlled trials, and the largest real-world patient study.3-6

GET DATA FIRST
The Medtronic Symplicity Spyral Multi-Electrode Renal Denervation (RDN) catheter, part of the Symplicity Spyral RDN system that helps reduce high blood pressure (HBP) in hypertensive patients.
A graphic showing the average drop in office systolic blood pressure after three years among patients in the GLOBAL SYMPLICITY REGISTRY, which is 16.7 mmHg.
A graphic showing the average drop in office systolic blood pressure after six months among patients in the SPYRAL HTN-ON MED pilot study, which was 9.4 mmHg.
A graphic showing the average drop in office systolic blood pressure after three months among patients in the SPYRAL HTN-OFF MED Pivotal trial, which was 9.2 mmHg.

CLINICAL EVIDENCE COVERS MORE THAN 12,000 PATIENT-YEARS OF FOLLOW-UPS

VIEW CLINICAL SUMMARIES

LONG-TERM DATA ABOUT SAFETY AND EFFICACY

The GLOBAL SYMPLICITY REGISTRY confirms safety and efficacy in the real world through three years in a variety of patients representative of daily clinical practice.3

REVIEW THE FINDINGS
Play Video This will play a video - Dr. Markus Schlaich

Prof. Markus Schlaich discusses GLOBAL SYMPLICITY REGISTRY data on RDN in patients with resistant hypertension.

RDN INSIGHTS  FROM TCT CONNECT 2020

Watch interviews with experts on the latest data in RDN from TCT Connect 2020.

Play Video This will play a video - Dr. Andrew Sharp

Prof. Andrew Sharp reviews data on the durability of RDN from animal histology and insights into human renal anatomy.

RIGOROUS TESTING OF RDN

The SPYRAL HTN Global Clinical Trial program is a multi-phase, global study program.

SEE THE RESULTS

LONG-TERM DATA ABOUT SAFETY AND EFFICACY

GLOBAL SYMPLICITY REGISTRY confirms safety and efficacy in the real world through three years in a variety of patients representative of daily clinical practice.7

REVIEW THE FINDINGS

EXPLORE THE SYMPLICITY SPYRAL™ PROCEDURE

Review detailed information about the RDN procedure using RF ablation with the Medtronic Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter.

SEE THE PROCEDURE
The Medtronic Symplicity Spyral Multi-Electrode Renal Denervation (RDN) catheter, part of the Symplicity Spyral RDN system that helps reduce high blood pressure (HBP) in hypertensive patients.

RDN IN CLINICAL PRACTICE

Find a wide range of scientific and practical information for deploying RDN in patient practice at this Wondr Medical channel.

VISIT WONDR

CME COURSES FOR RDN

Medscape offers several continuing medical education (CME) courses on RDN, clinical data, and other topics.

VISIT MEDSCAPE

WANT TO LEARN MORE ABOUT RDN?

Receive new data as it becomes available.

SEE NEW DATA FIRST
*

Patients enrolled in Medtronic-sponsored, funded or physician-initiated studies.

RDN arm reduction from baseline.

ANCOVA adjusted; secondary efficacy analysis.

1

Lewington S. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet. 2002;360(9349):1903-1913.

2

Data on file, Medtronic. April 2021.

3

Mahfoud F, Mancia G, Schmieder R, et al. Three-year safety and efficacy in the Global Symplicity Registry: Impact of antihypertensive medication burden on blood pressure reduction. Presented at PCR e-course 2020.

4

Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. The Lancet. 2018 Jun 9;391(10137):2346-2355.

5

Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. The Lancet 2020; Published online March 29, 2020. DOI:10.1016/S0140-6736(20)30554-7.

6

Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. The Lancet. 2017; 390:2160–2170.

7

Mahfoud F, Mancia G, Schmieder R, et. al. Renal Denervation in high-risk patients with hypertension. Journal of the American College of Cardiology. 2020; 75(23): 2879-2888.